Related Experiment Video
Updated: Jun 21, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis
1Baqiyatallah University of Medical Sciences, Research Center for Gastroenterology and Liver Disease, Tehran, Iran. editor@hepmon.com
Insights
Hepatitis C virus (HCV) treatment in thalassaemia patients shows a 44.7% sustained virological response. Adding ribavirin benefits Genotype 1 infections, though it may increase transfusion needs without significant adverse events.
Area of Science:
- Hepatology
- Virology
- Hematology
Background:
- Hepatitis C virus (HCV) infection poses significant risks for liver disease and mortality in thalassaemia patients.
- Effective anti-HCV treatment strategies are crucial for this vulnerable population.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy of current anti-HCV treatments in thalassaemic patients.
- To evaluate the sustained virological response (SVR) rates and treatment outcomes.
Main Methods:
- Systematic review and meta-analysis of 13 articles including prospective cohort studies, a randomized-controlled trial, and controlled trials.
- Inclusion of data from 429 thalassaemic patients treated with interferon-based therapies (monotherapy or combination with ribavirin).
- Analysis of comparative (odds ratio) and non-comparative (success rate) indices for SVR.
Main Results:
- The pooled SVR rate across all treatments was 44.7%.
- Thalassaemic patients with HCV Genotype 1 infection showed a significantly higher SVR when treated with ribavirin combination therapy (OR: 1.7) compared to interferon monotherapy (OR: 0.46).
- Ribavirin use was associated with a 30-40% increase in transfusion needs but did not significantly increase major adverse events or treatment withdrawal.
Conclusions:
- The addition of ribavirin to interferon-based therapy significantly benefits thalassaemic patients with HCV Genotype 1 infection.
- While ribavirin may increase transfusion requirements, it appears safe and effective in this population.
- Further research is needed to clarify the role of pegylated interferon (PEG-IFN) in thalassaemic patients.
Abstract:
Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality among thalassaemic patients. In order to analyse the effect of the current anti-HCV treatment in this subset of HCV-infected patients, we conducted a systematic review with meta-analysis of the available literature. The outcome was sustained viral response. Both comparative [odds ratio (OR)] and non-comparative indeces (success rate) were used to run the meta-analytical procedure. Data encompassing 429 thalassaemic HCV-infected patients treated with conventional or pegylated interferon monotherapy or combination therapy with ribavirin were collected from 13 articles (10 prospective cohort studies, 1 randomized-controlled trial and 2 controlled trials). Pooled sustained viralogical response (SVR) was 44.7% (34.6-54.9). Pooled ORs of SVR for Genotype 1 vs non-Genotype 1 infected thalassaemic patients were 0.46 (95% CI: 0.22-0.95) in IFN monotherapy and 1.7 (95% CI: 0.46-6.04) in ribavirin combination therapy. Our meta-analysis shows that thalassaemic patients with Genotype 1 infection significantly benefit from the addition of ribavirin to their therapeutic regimen. It seems that using ribavirin in thalassaemic patients increases transfusion need by a median of 30-40%, but does not increase major adverse events or treatment withdrawal. Current literature is lacking sufficient evidence about the use of PEG-IFN as monotherapy or in combination with ribavirin in thalassaemic patients.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:25Hepatitis